STOCKHOLDERS' EQUITY (Tables)

9 Months Ended

Mar. 31, 2016

Stockholders Equity Note [Line Items]

Schedule of Stock Option Activity

	Nine months ended March 31, 2016 (Unaudited)
	Number	Weighted Average Exercise Price	Weighted Average Remaining Contractual Terms (in years)	Aggregate Intrinsic Value Price
Options outstanding at beginning of period	1,836,900	$  3.72
Options forfeited	(37,200)	$  4.40
Options exercised	(28,000)	$        0.62
Options outstanding at end of the period	1,771,700	$ 3.76	1.40	$ 382
Options exercisable at the end of the period	1,771,700	$ 3.76	1.40	$ 382
Options vested	1,771,700	$ 3.76	1.40	$ 382

Schedule of Stock Option and Warrant Activity

	Nine months ended March 31, 2016 (Unaudited)
	Number	Weighted Average Exercise Price	Weighted Average Remaining Contractual Terms (in years)	Aggregate Intrinsic Value Price
Options and warrants outstanding at beginning of period	228,000	$ 5.19
Options granted	1,800	$ 0.00
Options forfeited	(6,000)	$ 4.40
Options and warrants outstanding at end of the period	223,800	$ 5.72	2.23	$133
Options and warrants exercisable at the end of the period	221,500	$ 5.78	2.16	$131
Options not vested, expected to vest	2,300	$ 0.00	8.78	$2

Restricted stock units [Member]

Stockholders Equity Note [Line Items]

Schedule of Unvested Restricted Stock Units

	Number
Unvested at the beginning of period	1,732,383
Granted	1,461,431
Forfeited	(78,601)
Vested	(1,009,783)
Unvested at the end of the period	2,105,430
Expected to vest after  March 31, 2016	2,028,054

Schedule of Stock-based Compensation Expenses

	Nine months ended March 31,		Three months ended March 31,
	2016	2015	2016	2015
	(Unaudited)		(Unaudited)
Research and development expenses	$ 743	$ 977	$ 260	$ 482
General and administrative expenses	1,496	1,735	476	592
	$     2,239	$      2,712	$        736	$     1,074

Consultant Restricted Stock Units [Member]

Stockholders Equity Note [Line Items]

Schedule of Unvested Restricted Stock Units

	Number
Unvested at the beginning of period	28,385
Granted	152,257
Vested	(180,142)
Unvested at the end of the period	500

Schedule of Stock-based Compensation Expenses

	Nine months ended March 31,			Three months ended March 31,
	2016		2015	2016		2015
	(Unaudited)			(Unaudited)
Research and development expenses	$ 26	$ 110		$ 6	$ 33
General and administrative expenses	100	88		52	50
	$ 126	$ 198		$ 58	$ 83

Options And Warrants [Member]

Stockholders Equity Note [Line Items]

Schedule of Stock-based Compensation Expenses

	Nine months ended March 31,		Three months ended March 31,
	2016	2015	2016	2015
	(Unaudited)		(Unaudited)
Research and development expenses	$            -	$            1	$            -	$            -
General and administrative expenses	$            2	$            1	$            1	$            1
	$            2	$            2	$            1	$            1